|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.0110 - 0.0110|
|52 Week Range||0.0110 - 0.3700|
|Beta (5Y Monthly)||0.06|
|PE Ratio (TTM)||0.28|
|Forward Dividend & Yield||0.01 (132.39%)|
|Ex-Dividend Date||Sep 30, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for NEGXF
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce its interim financial results for the third quarter ended September 30, 2022, highlighted by continued revenue growth, positive EBIDTA and increased free cash flow. During Q3 2022, the Company showed revenue growth of 15.81% over the same period last year. Revenue for the third quarter was $3,317,358 and $9,401,460 year-to-date.
NexgenRx (CVE:NXG) has had a rough three months with its share price down 19%. However, stock prices are usually driven...
NEXGENRX INC.("NexgenRx" or the "Company") is pleased to announce that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before October 10, 2022 to all shareholders of record as at the close of business on October 3, 2022.